More recently, studies suggested that PSMA targeting may improve tumor-tissue yield from CT-guided bone biopsies in prostate cancer patients, but CT attenuation of biopsied lesions was not reported in the available data and needs to be evaluated in the future [16, 17]. This evidence concerns the gene FOLH1 and prostate cancer.